Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 44

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 44
---
/prospectus because the information in this section does not provide all the information that might be important to you with respect to the Proposals and the other matters being considered at the Meeting. Additional important information is also contained in the annexes to and the documents incorporated by reference into this proxy statement/prospectus. QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION

| Q: | What will happen in the Business Combination? |

| A: | Denali, Merger Sub, and Semnur have agreed to the Business Combination under the terms of the Merger Agreement, Amendment No. 1 to Merger Agreement and Amendment No. 2 to Merger Agreement, which are attached to this proxy statement/prospectus as Annex A-1, Annex A-2 and Annex A-3, respectively, and are incorporated into this proxy statement/prospectus by reference. Pursuant to the Merger Agreement, prior to the Effective Time, Denali will change its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. See “Proposal 2 — The Domestication Proposal” for further information on the Domestication. In addition, following the Domestication and at the Effective Time, Merger Sub will merge with and into Semnur, with Semnur continuing as the surviving entity and wholly owned subsidiary of Denali. |

In connection with the Business Combination, the cash held in the Trust Account after giving effect to any redemption of shares by Denali’s public shareholders will be used to pay certain fees and expenses in connection with the Business Combination, and for working capital and general corporate purposes.

| Q: | Why am I receiving this proxy statement/prospectus? |

YOUR VOTE IS IMPORTANT. YOU ARE ENCOURAGED TO SUBMIT YOUR PROXY AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS PROXY STATEMENT/PROSPECTUS AND ITS ANNEXES AND CAREFULLY CONSIDERING EACH OF THE PROPOSALS BEING PRESENTED AT THE MEETING.

| Q: | What is the consideration being paid to Semnur securityholders? |

| A: | If the Business Combination is completed: (i) each outstanding share of Semnur Common Stock as of immediately prior to the Effective Time (other than shares held by Semnur or its subsidiaries or shares the holders of which exercise dissenters’ rights of appraisal) will be automatically converted into the right to receive